nach oben

Current Dermatology Reports

Erschienen in:

21.11.2019 | Veterinary Dermatology (A Rostaher and N Fischer)

Allergen Specific Immunotherapy in Canine Atopic Dermatitis: an Update

verfasst von: Nina M. Fischer, Ralf S. Müller

Erschienen in: Current Dermatology Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review aims to evaluate new insights into allergen immunotherapy (AIT) and review the mechanism, different protocols used, and response rate of this treatment option for canine atopic dermatitis.

Recent Findings

AIT is the only etiological treatment available for canine atopic dermatitis. Selection of allergens is based on clinical history in conjunction with positive reactions on intradermal and serum testing. During decades AIT was applied subcutaneously (SCIT) using aqueous or aluminum-precipitated solution of allergens, but in the last few years, new routes like sublingual (SLIT), intralymphatic (ILIT), and epicutaneous administration are on the rise. AIT combines a satisfactory success rate (around 70%) with a good safety profile. Adverse effects include mainly increased pruritus and anaphylactic reactions are rarely seen in animals. Pilot studies with different adjuvants to further increase safety and efficacy have been published.

Summary

AIT is a safe and effective therapy for canine atopic dermatitis. However, as most of the published studies are case series with often rather small numbers of animals included, more and larger randomized studies of immunotherapy are needed in a clinical setting to provide guidance on the optimal selection of allergens, adjuvants, dosing, success rate, and adverse effects of the various protocols of immunotherapy in dogs.

Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol. 2006;114(3–4):207–8. https://doi.org/10.1016/j.vetimm.2006.08.013.CrossRefPubMed

Marsella R, Sousa CA, Gonzales AJ, Fadok VA. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J Am Vet Med Assoc. 2012;241(2):194–207. https://doi.org/10.2460/javma.241.2.194.CrossRefPubMed

Nuttall T, Uri M, Halliwell R. Canine atopic dermatitis- what have we learned? Vet Rec. 2013;172(8):201–7. https://doi.org/10.1136/vr.f1134.CrossRefPubMed

Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol. 2001;81:363–84.CrossRef

Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. Vet Dermatol. 2009;20(2):84–98. https://doi.org/10.1111/j.1365-3164.2008.00727.x.CrossRefPubMed

Maggi E. T-cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol. 2010;161(1):10–8. https://doi.org/10.1111/j.1365-2249.2010.04148.x.CrossRefPubMedPubMedCentral

•• Mueller RS, Jensen-Jarolim E, Roth-Walter F, Marti E, Janda J, Seida AA, et al. Allergen immunotherapy in people, dogs, cats and horses - differences, similarities and research needs. Allergy. 2018;73(10):1989–99. https://doi.org/10.1111/all.13464High level review article on immunotherapy in animals and humans. Very up to date information on all imprortant aspects of immunotherapy in all species. CrossRefPubMed

Willemse A, van den Brom WE, Rijnberg A. Effect of hyposensitization on atopic dermatitis in dogs. J Am Vet Med Assn. 1984;184:1277–80.

Schnabl B, Bettenay SV, Dow K, Mueller RS. Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec. 2006;158(3):81–5.CrossRef

10.

Mueller RSFK, Zabel S, Rosychuk RAW. Conventional and rush immunotherapy in canine atopic dermatitis. In: Hillier A, Foster AP, Kwochka KW, editors. Advances in veterinary dermatology. Oxford: Blackwell Publishing; 2005. p. 60–9.

11.

• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127(1):18–27. https://doi.org/10.1016/j.jaci.2010.11.030 quiz 8–9. Review article, which sums up the suspected mechanism of AIT. CrossRefPubMed

12.

Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556–68. https://doi.org/10.1016/j.jaci.2015.04.047.CrossRefPubMed

13.

Jutel M, Kosowska A, Smolinska S. Allergen immunotherapy: past, present, and future. Allergy, Asthma Immunol Res. 2016;8(3):191–7. https://doi.org/10.4168/aair.2016.8.3.191.CrossRef

14.

DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). Vet Dermatol. 2016;27:82–e24. https://doi.org/10.1111/vde.12284.CrossRefPubMed

15.

Ozmen I, Marsella R. Sublingual immunotherapy in human and canine atopic dermatitis: a mini review. Vet. Sci. 2014, 1(3), 136-149CrossRef

16.

Hatzmann KMR. Practicability and safety of intralymphatic allergen-specific immunotherapy in dogs with atopic dermatitis. J Vet Dermatol. 2011;22: 463-464 (Abstract).

17.

• Fischer N, Rostaher A, Favrot C. Intralymphatic immunotherapy: an effective and safe alternative route for canine atopic dermatitis. Schweiz Arch Tierheilkd. 2016;158(9):646–52. https://doi.org/10.17236/sat00085Up to date study on the efficacy and safety of intralymphatic immunotherapy in dogs. CrossRefPubMed

18.

Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129(1):128–35. https://doi.org/10.1016/j.jaci.2011.08.036.CrossRefPubMed

19.

•• Mueller RS, Janda J, Jensen-Jarolim E, Rhyner C, Marti E. Allergens in veterinary medicine. Allergy. 2016;71(1):27–35. https://doi.org/10.1111/all.12726High level and up to date review about allergens and allergy testing in veterinary medicine. CrossRefPubMed

20.

• Fischer N, Tarpataki N, Leidi F, Rostaher A, Favrot C. An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland. Vet Dermatol. 2018;29:337–e118. https://doi.org/10.1111/vde.12657. Up to date study on the efficacy and safety of the first recombinant immunotherapy use in dogs. CrossRef

21.

• Kawano K, Mizuno T. A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis. Vet Dermatol. 2017;28(6):583–e141. https://doi.org/10.1111/vde.12470Up to date study on the efficacy and safety of the first recombinant immunotherapy use in dogs. CrossRefPubMed

22.

Sahin E, Bafaqeeh SA, Guven SG, Cetinkaya EA, Muluk NB, Coskun ZO, et al. Mechanism of action of allergen immunotherapy. Am J Rhinol Allergy. 2016;30(5):1–3. https://doi.org/10.2500/ajra.2016.30.4367.CrossRefPubMed

23.

Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621–31. https://doi.org/10.1016/j.jaci.2013.12.1088.CrossRefPubMed

24.

Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17. https://doi.org/10.1186/s40413-015-0063-2.CrossRefPubMed

25.

Jutel M, Van de Veen W, Agache I, Azkur KA, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int. 2013;62(4):425–33. https://doi.org/10.2332/allergolint.13-RAI-0608.CrossRefPubMed

26.

Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest. 1976;57(5):1378–85. https://doi.org/10.1172/JCI108406.CrossRefPubMedPubMedCentral

27.

Till SJ, Durham SR. Immunological responses to allergen immunotherapy. Clin Allergy Immunol. 2004;18:85–104.PubMed

28.

Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy. 1997;27(9):1007–15.CrossRef

29.

Hou CC, Griffin CE, Hill PB. Dermatophagoides farinae-specific IgG responses in atopic dogs undergoing allergen-specific immunotherapy with aqueous vaccines. Vet Dermatol. 2008;19(4):215–20.CrossRef

30.

Hites MJ, Kleinbeck ML, Loker JL, Lee KW. Effect of immunotherapy on the serum concentrations of allergen-specific IgG antibodies in dog sera. Vet Immunol Immunopathol. 1989;22(1):39–51.CrossRef

31.

Keppel KE, Campbell KL, Zuckermann FA, Greeley EA, Schaeffer DJ, Husmann RJ. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy. Vet Immunol Immunopathol. 2008;123(3–4):337–44. https://doi.org/10.1016/j.vetimm.2008.02.008.CrossRefPubMed

32.

Lian TMHR. Allergen-specific IgE and IgG antibodies in atopic and normal dogs. Vet Immunol Immunopathol. 1998;66(3–4):203–23.CrossRef

33.

Mueller RS, Fieseler KV, Rosychuk RA, Greenwalt T. Intradermal testing with the storage mite Tyrophagus putrescentiae in normal dogs and dogs with atopic dermatitis in Colorado. Vet Dermatol. 2005;16(1):27–31. https://doi.org/10.1111/j.1365-3164.2005.00415.x.CrossRefPubMed

34.

Gedon NKY, Boehm T, Klinger CJ, Udraite L, Mueller RS. Agreement of serum allergen test results with unblocked and blocked IgE against cross-reactive carbohydrate determinants (CCD) and intradermal test results in atopic dogs. Vet Dermatol. 2019;30(3):195–e61. https://doi.org/10.1111/vde.12742.CrossRefPubMed

35.

Willemse T, Bardagi M, Carlotti DN, Ferrer L, Fondati A, Fontaine J, et al. Dermatophagoides farinae-specific immunotherapy in atopic dogs with hypersensitivity to multiple allergens: a randomised, double blind, placebo-controlled study. Vet J. 2009;180(3):337–42. https://doi.org/10.1016/j.tvjl.2008.01.004.CrossRefPubMed

36.

Plant JD, Neradilek MB. Effectiveness of regionally-specific immunotherapy for the management of canine atopic dermatitis. BMC Vet Res. 2017;13(1):4–6. https://doi.org/10.1186/s12917-016-0917-z.CrossRefPubMedPubMedCentral

37.

Telia AA, Telia AZ, Machavariani K, Telia Z. Sublingual immunotherapy for allergic asthma and rhinitis. Georgian Med News. 2018;276:123–30.

38.

Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol Med. 2008;14(5):191–8. https://doi.org/10.1016/j.molmed.2008.03.001.CrossRefPubMed

39.

• Timm K, Mueller RS, Nett-Mettler CS. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis. Vet Dermatol. 2018;29(2):123–e49. https://doi.org/10.1111/vde.12517Up to date study on the efficacy and safety of intralymphatic immunotherapy in dogs. CrossRefPubMed

40.

• Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290–6. https://doi.org/10.1016/j.jaci.2012.02.026This article is one of the first introducing intralymphatic immunotherapy. It’s a human study stating the advantages of fast efficacy and safety in comparison to subcutaneous immunotherapy. CrossRefPubMed

41.

• Hobi S, Mueller RS. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2014;42(3):167–73 An up to date study on rush immunotherapy used in veterinary dermatology. This study shows the advantages of this immunotherapy protocol. PubMed

42.

Fujimura M, Ishimaru H. Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study. Pol J Vet Sci. 2016;19(1):3–6. https://doi.org/10.1515/pjvs-2016-0001.CrossRefPubMed

43.

Mueller RS, Bettenay SV. Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. Am J Vet Res. 2001;62(3):307–10.CrossRef

44.

Bozek A, Kolodziejczyk K. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy. Hum Vaccin Immunother. 2018;14(2):288–91. https://doi.org/10.1080/21645515.2017.1397245.CrossRefPubMed

45.

Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E, et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(Suppl 82):1–20. https://doi.org/10.1111/j.1398-9995.2006.01219_1.x.CrossRefPubMed

46.

Uchida T, Ikegami H, Ando S, Kurimoto M, Mitsuhashi M, Naito S, et al. Suppression of murine IgE responses with ovalbumin-pullulan conjugates: comparison of the suppressive effect of different conjugation methods and different molecular weights of pullulan. Int Arch Allergy Immunol. 1993;102(3):276–8.CrossRef

47.

Manzano AI, Javier Canada F, Cases B, Sirvent S, Soria I, Palomares O, et al. Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. Glycoconj J. 2016;33(1):93–101. https://doi.org/10.1007/s10719-015-9640-4.CrossRefPubMed

48.

Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM, et al. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. J Allergy Clin Immunol. 2016;138(2):558–67 e11. https://doi.org/10.1016/j.jaci.2016.02.029.CrossRefPubMed

49.

Gonzalez JL, Zalve V, Fernandez-Caldas E, Cases B, Subiza JL, Casanovas M. A pilot study of immunotherapy in dogs with atopic dermatitis using a mannan-Dermatophagoides farinae allergoid targeting dendritic cells. Vet Dermatol. 2018;29(5):449–e152. https://doi.org/10.1111/vde.12679.CrossRefPubMed

50.

Kolaczek A, Skorupa D, Antczak-Marczak M, Kuna P, Kupczyk M. Safety and efficacy of venom immunotherapy: a real life study. Postepy Dermatol Alergol. 2017;34(2):159–67. https://doi.org/10.5114/ada.2017.67082.CrossRefPubMedPubMedCentral

51.

Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992;89(2):529–35. https://doi.org/10.1016/0091-6749(92)90319-w.CrossRefPubMed

52.

Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol. 2010;126(1):105–11 e5. https://doi.org/10.1016/j.jaci.2010.04.025.CrossRefPubMed

53.

•• Mueller RS. Update on allergen immunotherapy. Vet Clin N Am-Small. 2019;49(1):1–7. https://doi.org/10.1016/j.cvsm.2018.08.001. Review article on immunotherapy in animals. Very up to date information on all imprortant aspects of immunotherapy in cats and dogs. CrossRef

54.

Shida M, Kadoya M, Park SJ, Nishifuji K, Momoi Y, Iwasaki T. Allergen-specific immunotherapy induces Th1 shift in dogs with atopic dermatitis. Vet Immunol Immunopathol. 2004;102(1–2):19–31. https://doi.org/10.1016/j.vetimm.2004.06.003.CrossRefPubMed

55.

• Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol. 2001;81(3–4):363–83 Although this review article is quiet old—it still serves as high importance since it’s the summerized opinion of leading dermatologists (ACVD taskt force) on the topic of immunotherapy. CrossRef

56.

Scott DW. Observations on canine atopy. J Am Anim Hosp Assoc. 1981;17(1):91–100.

57.

Marsella R, Ahrens K. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs. Vet Dermatol. 2018;29(5):439–e146. https://doi.org/10.1111/vde.12660.CrossRefPubMed

Titel: Allergen Specific Immunotherapy in Canine Atopic Dermatitis: an Update
verfasst von: Nina M. Fischer
Ralf S. Müller
Publikationsdatum: 21.11.2019
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 4/2019
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-019-00276-z

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Allergen Specific Immunotherapy in Canine Atopic Dermatitis: an Update

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Inpatient Management of Autoimmune Blistering Diseases: an Update, Review, and Practical Guide

Non-invasive Imaging for Skin Cancers—the European Experience

A Review of Botanicals Exhibiting Antifungal Activity Against Malassezia spp. Implicated in Common Skin Conditions

Paraneoplastic Syndromes for the Inpatient Dermatologist

New Strategies for Prevention and Treatment of Insect Bite Hypersensitivity in Horses

Lymphedema: New Concepts in Diagnosis and Treatment

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie